Randomized trial examines cognitive decline prediction in Parkinson's disease using combined CSF biomarkers, suggesting improved risk stratification.
Key Points
This study aims to determine if combining cerebrospinal fluid alpha-synuclein and amyloid-β42 better predicts cognitive decline and dementia risk in Parkinson's disease.
Included 692 participants from the Parkinson's Progression Markers Initiative.
Classified participants into four groups based on alpha-synuclein and amyloid-β42 status.
Performed multivariable Cox regression analyses for dementia risk.
α-synuclein SAA positivity was 87.2% at baseline in participants with PD.
Each increase in biomarker category increased dementia hazard (HR = 2.72, 95% CI 1.80–4.08, p < 0.001).
S + A+ group showed the steepest cognitive decline (p < 0.001) compared to other groups.